Overexpression of microRNA-1470 promotes proliferation and migration, and inhibits senescence of esophageal squamous carcinoma cells

LI-LI MEI1, YUN-TAN QIU1, WEN-JUN WANG1, JIE BAI1 and ZHI-ZHOU SHI1,2

1Medical School, Kunming University of Science and Technology, Kunming, Yunnan 650500; 2State Key Laboratory of Molecular Oncology, Cancer Hospital, CAMS, Beijing 100021, P.R. China

Received September 30, 2016; Accepted August 11, 2017

DOI: 10.3892/ol.2017.7190

Abstract. MicroRNA-1470 (miR-1470) is overexpressed in esophageal squamous cell carcinoma (ESCC); however, its role and underlying molecular mechanism remain unknown. The aim of the present study was to explore the tumorigenic role and mechanism of miR-1470 overexpression in ESCC. The expression of miR-1470 in ESCC tissues and cell lines was detected using human miRNA microarrays and the reverse transcription-quantitative polymerase chain reaction, respectively. The effects of miR-1470 on cell proliferation, migration and senescence were determined using a Cell Counting Kit-8 assay, Transwell migration assay and β-galactosidase staining kit. Western blotting was used to analyze the expression levels of genes in the apoptosis signaling pathway. An increased expression level of miR-1470 was observed in ESCC tissues compared with that in para-cancerous tissues. Knockdown of miR-1470 significantly suppressed proliferation, and down-regulated the cell cycle regulatory gene cyclin E1. It was also revealed that knockdown of miR-1470 significantly inhibited migration, and decreased the expression levels of matrix metalloproteinase 2 (MMP2), MMP13 and MMP14. Western blotting analysis revealed that knockdown of miR-1470 induced apoptosis by increasing B-cell lymphoma 2 (Bcl-2) expression. The results of the present study suggest that overexpression of miR-1470 in ESCC promotes cancer cell proliferation by accelerating the cell cycle and inhibiting apoptosis, and also enhances cancer cell migration by upregulating MMPs.

Introduction

Esophageal squamous cell carcinoma (ESCC) is one of the most common malignant diseases globally, particularly in China, where it is the fourth most common cause of cancer-associated mortality (1-3). Currently, there are limited clinical approaches towards the early diagnosis and treatment of ESCC, resulting in a 10% 5-year survival rate for patients (4). Thus, clarification of the molecular mechanisms underlying the pathogenesis of ESCC and development of therapeutic strategies are urgently required.

MicroRNAs (miRNAs) are small non-coding RNAs (between 18 and 22 nucleotides in length), which serve a role in gene expression regulation primarily by repressing translation (5,6). Prior evidence supports the notion that miRNAs modulate proliferation, apoptosis, metastasis and metabolism of cancer (6,7). Numerous miRNAs are involved in esophageal tumorigenesis (8,9). However, the role of miRNA-1470 (miR-1470) in esophageal cancer progression remains undefined.

Bcl-2 is an apoptosis inhibitor (10). When Bcl-2 is suppressed, tumor cells undergo apoptosis and cease proliferation (11). Various moderators of apoptosis exert their effects through the caspase enzyme system. Among them, caspase-3 has been demonstrated to be the most markedly associated with apoptosis (12,13). Furthermore, decreased caspase-3 expression has been observed in several human malignancies including oral squamous cell carcinoma, non-small cell lung carcinoma, breast cancer, gastric cancer, and ESCC (14-17). Overexpressions of Bcl-2 and other apoptotic inhibitors serve the roles in therapeutic resistance of ESCC (18,19). Whereas decreased Bcl-2 expression promotes apoptotic responses to anticancer drugs, increased expression of Bcl-2 leads to resistance to chemotherapy drugs and radiation therapy. The inhibition of cell apoptosis is associated with the onset and development of cancer, as well as its sensitivity to chemotherapy (19-21).

In the present study, it was demonstrated that miR-1470 was upregulated in ESCC tissues, and knockdown of miR-1470 significantly inhibited proliferation and migration, and promoted senescence, of ESCC cells. Furthermore, knockdown of miR-1470 exhibited apoptosis-promoting activity,
including downregulation of the anti-apoptotic protein Bcl-2 and upregulation of the pro-apoptotic Bcl-2-associated X protein (BAX). Taken together, the results of the present study suggest that miR-1470 affects cancer progression via the regulation of Bcl-2 expression and may be a promising therapeutic target for the treatment of ESCC.

Materials and methods

Cell culture and transfection. The ESCC cell lines including KYSE30, KYSE180, KYSE450, KYSE150 and KYSE510, provided by Dr Yutaka Shimada (Kyoto University, Kyoto, Japan), were cultured in RPMI-1640 medium (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA) with 10% fetal bovine serum (FBS; Hyclone; GE Healthcare Life Sciences, Logan, UT, USA). All cells were maintained at 37°C with 5% CO₂. Homo sapiens (hsa)-miR-1470 inhibitor was designed and provided by Shanghai GenePharma, Co., Ltd. (Shanghai, China). Transfection was performed using Lipofectamine 2000 (Invitrogen; Thermo Fisher Scientific, Inc. Carlsbad, USA), according to the manufacturer’s protocol. Transfected cells were incubated at 37°C with 5% CO₂ for 48 h.

The sequence of the miR-1470 inhibitor was 5'-CGGGGU GCACGGGCGAGGGCC-3'; the sequence of the negative control was 5'-CAGUACUUUUGUGUAGUCAA-3'..

Cell proliferation assay. Cells were seeded in 96-well flat-bottomed plates, with each well containing 2x10³ cells in 100 µl cell suspension. After incubation for 24, 48, 72 h and 96 h, cell viability was determined using the Cell Counting Kit-8 assay (CCK-8; Dojindo Molecular Technologies, Inc., Kumamoto, Japan), according to the manufacturer’s protocol using a microplate read at 450 nm. Each experiment, with 6 replicates, was repeated in triplicate.

Cell migration assay. Cells (5x10⁵ cells in serum-free RPMI-1640 medium) were seeded in the upper chamber. The wells in the lower chamber were filled with RPMI-1640 medium containing 20% FBS, and incubated at 37°C for 36 h. Cells on the upper membrane surface were wiped off using a cotton swab, and the lower membrane surface was fixed with methanol and stained with 0.1% crystal violet. Each experiment was repeated in triplicate.

Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) assay. RT-qPCR was performed using the Premix Ex Taq kit (Takara Biotechnology Co., Ltd., Dalian, China) and a 7300 Real-Time PCR system (Thermo Fisher Scientific, Inc., Shanghai, China) and a 7300 Real-Time PCR system (Thermo Fisher Scientific, Inc., Shanghai, China) was subsequently added to lyse cells and cells were incubated on ice for protein extraction. Protein concentration was determined using the Bicinchoninic Acid Protein Assay Kit (Beyotime Institute of Biotechnology, Haimen, China). Protein samples were separated by SDS-PAGE (12% gel) and transferred onto a polyvinylidene difluoride membrane (Merck KGaA, Darmstadt, Germany). The membrane was soaked in 10% skimmed milk (in PBS, pH 7.2, containing 0.1% Tween-20) for 2 h at 4°C and incubated with an appropriate amount of primary antibody [working dilutions of antibodies: Bcl-2, 1:1,000, cat. no. 10783-1-AP; BAX, 1:1,000, cat. no. 23931-1-AP (both Proteintech Group, Inc., Logan, UT, USA) pro-caspase-3, 1:1,000, cat. no. sc-7148; pro-caspase-12, 1:1,000, cat. no. sc-5627; β-actin, 1:400, cat. no. sc-7754]. The expression of protein was normalized against an appropriate amount of primary antibody [working dilutions of antibodies: Bcl-2, 1:1,000, cat. no. 10783-1-AP; BAX, 1:1,000, cat. no. 23931-1-AP (both Proteintech Group, Inc., Chicago, IL, USA) pro-caspase-3, 1:1,000, cat. no. sc-7148; pro-caspase-12, 1:1,000, cat. no. sc-5627; β-actin, 1:400, cat. no. sc-7754]. Western blotting. Cells from each group were detached with trypsin, centrifuged at 1,000 x g for 5 min at 4°C and washed twice with pre-chilled PBS. Radioimmunoprecipitation Assay buffer (Beyotime Institute of Biotechnology, Haimen, China) was subsequently added to lyse cells and cells were incubated on ice for protein extraction. Protein concentration was determined using the Bicinchoninic Acid Protein Assay kit (Beyotime Institute of Biotechnology, Equal amounts (10 µg per lane) of proteins were separated by SDS-PAGE (12% gel) and transferred onto a polyvinylidene difluoride membrane (Merck KGaA, Darmstadt, Germany). The membrane was soaked in 10% skimmed milk (in PBS, pH 7.2, containing 0.1% Tween-20) for 2 h at 4°C and incubated with an appropriate amount of primary antibody [working dilutions of antibodies: Bcl-2, 1:1,000, cat. no. 10783-1-AP; BAX, 1:1,000, cat. no. 23931-1-AP (both Proteintech Group, Inc., Chicago, IL, USA) pro-caspase-3, 1:1,000, cat. no. sc-7148; pro-caspase-12, 1:1,000, cat. no. sc-5627; β-actin, 1:400, cat. no. sc-7754].
peroxidase-conjugated secondary antibodies (anti-mouse IgG, 1:10,000; cat. no. 474-1806 or anti-rabbit IgG, 1:10,000; cat. no. 5450-0010) for 2 h at room temperature (KPL, Inc., Gaithersburg, MD, USA) and Immobilon™ Western chemiluminescent HRP substrate kit (EMD Millipore, Billerica, MA, USA). Densitometry analysis was performed using ImageJ 1.46 software (National Institutes of Health, Bethesda, MD, USA).

Assessment of senescence. To assess senescence, β-galactosidase activity was measured using a Senescence β-Galactosidase Staining kit (Cell Signaling Technology, Inc., Danvers, MA, USA) and performed according to the manufacturer's protocol. Briefly, negative control (NC)-or miRNA-1470 inhibitor-transfected cells were washed twice with 1X PBS, fixed in 1X fixation buffer for 5 min, washed three times with 1X PBS and incubated with the staining mixture overnight at 37°C. β-galactosidase-positive cells were visualized as blue cells when examined using a light microscope (magnification, x400). For NC- and miRNA-1470 inhibitor-transfected cells, a total of 100 cells were counted from different fields of the plate, and the percentage of blue cells was calculated.

Statistical analysis. All results were confirmed in at least three independent experiments, and data from one representative experiment are presented. Student's t-test was used to compare the means of experimental groups. All quantitative data are presented as the mean ± standard deviation. The analysis was performed using GraphPad Prism (version 5.01; GraphPad Software, La Jolla, CA, USA). For all comparisons, P<0.05 was considered to indicate a statistically significant difference.

Results

ESCC tissues overexpress miR-1470. In the present study, it was revealed that the expression level of miR-1470 was increased in ESCC tissues compared with their adjacent non-malignant tissues using Agilent Human miRNA Microarrays (Fig. 1A). The expression of miR-1470 was further evaluated in 5

Figure 2. Downregulation of miR-1470 suppresses the proliferation and expression of cell cycle protein CCNE1 in KYSE150 and KYSE510 cells. (A) Level of miR-1470 in KYSE150 and KYSE510 cells with miR-1470 inhibitor and a negative control were detected using reverse transcription-quantitative polymerase chain reaction analysis. miR-1470 expression was normalized against an endogenous control U6. Cell proliferation was analyzed in miR-1470-knockdown and negative control (B) KYSE150 and (C) KYSE510 cells. (D) CCNE1 mRNA level in KYSE150 and KYSE510 cells following treatment with an miR-1470 inhibitor. *P<0.05, **P<0.01, ***P<0.001.
ESCC cell lines (KYSE30, KYSE180, KYSE450, KYSE150 and KYSE510) using RT-qPCR. The results revealed that KYSE150 and KYSE510 exhibited increased expression levels compared with other cell lines (Fig. 1B).

**Knockdown of miR-1470 suppresses proliferation of ESCC cells by regulating cell cycle regulatory protein.** To explore the role of miR-1470 in esophageal carcinogenesis, the cell viability was evaluated using a CCK-8 assay. Knockdown of miR-1470 using the inhibitor significantly inhibited proliferation of KYSE150 and KYSE510 cells (Fig. 2A-C). The mRNA level of the cell cycle regulatory gene CCNE1 in miR-1470 inhibitor-transfected cells were significantly decreased (Fig. 2D). These observations indicate that miR-1470 may promote cell proliferation via up-regulating CCNE1 in ESCC.

**Knockdown of miR-1470 inhibits the migration of ESCC cells by decreasing the expression of MMPs.** Using a Transwell assay, it was identified that knockdown of miR-1470 led to a decrease in the number of migratory KYSE150 and KYSE510 cells (Fig. 3A). Quantification and statistical analysis of the decrease in migratory cell numbers revealed that the difference was statistically significant (Fig. 3B). MMPs, a family of zinc-binding proteins, have been demonstrated to serve a role in tumor cell metastasis owing to their ability to degrade the extracellular matrix. Using RT-qPCR, we found that knockdown of miR-1470 significantly decreased the expression levels of MMP2, MMP13 and MMP14. Taken together, these data suggest that down-regulated miR-1470 may suppress the migration of ESCC cells via inhibition of MMPs.

**Suppression of miR-1470 induces senescence and activates apoptosis pathway in ESCC cells.** To investigate the effect of miR-1470 on cell senescence, morphological evaluation of KYSE150 and KYSE510 cells was performed following knockdown of miR-1470 expression. The results revealed an elongated phenotype resembling cellular senescence (Fig. 4A and B). As presented in Fig. 4C and D, compared with the control group, knockdown of miR-1470 markedly decreased anti-apoptotic protein Bcl-2, pro-caspase-12, pro-caspase-3 and increased pro-apoptotic protein BAX. These results suggest that suppression of miR-1470 may induce cell apoptosis.

**Discussion**

Previous studies have demonstrated that miRNAs are frequently dysregulated in numerous types of human cancer. As the roles of miRNAs in cancer are gradually investigated, their potential as a therapeutic target has
generated interest with regard to the development of novel strategies for treating cancer (22-24). Previous studies have characterized the miRNA expression profiles associated with distinct stages of ESCC, and dysregulation of miRNAs has been demonstrated to serve a role in esophageal carcinogenesis (25-28). miR-375 inhibits tumor growth and metastasis in ESCC through the suppression of insulin-like growth factor 1 receptor (27). Cui et al (29) demonstrated that targeting oncogenic phospholipase Cε1 using miR-145 impaired tumor proliferation and metastasis of ESCC. Although Nie et al (30) demonstrated that miR-1470 mediated lapatinib-induced p27 up-regulation by targeting c-jun, the expression status, role and underlying molecular oncogenic mechanism of miR-1470 in esophageal cancer progression remain to be established.

miR-1470 is located at 19p13.12. In the present study, upregulation of miR-1470 in ESCC tissues was revealed using microarray. Functional experiments further revealed that downregulation of miR-1470 significantly inhibited the proliferation of ESCC cells, and also decreased the level of the cell cycle regulatory gene CCNE1. To the best of our knowledge, prior to the present study there has been no reported association between miR-1470 and CCNE1. The results of the present study indicate that miR-1470 positively regulated CCNE1. The results suggest that upregulation of miR-1470 expression in ESCC promoted cell proliferation by accelerating cell cycle transition.

Metastasis is the primary cause of mortality in patients with ESCC. It was identified that downregulated miR-1470 expression inhibited the migration of ESCC cells in vitro. MMPs are proteolytic enzymes that serve a role in the transformation and progression of tumors at all stages, particularly during invasion and metastasis (31,32). In the present study, downregulation of miR-1470 significantly suppressed the expressions of MMP2, MMP13 and MMP14. The results suggested that overexpression of miR-1470 in ESCC promoted the migration of tumor cells via increasing the expression levels of MMPs.

Senescence generally contributes to the elimination of damaged cells by phagocytic cells, and to the subsequent promotion of tissue remodeling, in a similar manner to apoptosis (33). In the present study, knockdown of miR-1470 significantly induced cell senescence and activated the apoptotic signaling pathway.

In conclusion, it was demonstrated that downregulation of miR-1470 significantly inhibited ESCC cell proliferation and migration. The identification of miR-1470 provides insight into the pathogenesis of ESCC, and may represent a potential therapeutic target for the treatment of ESCC.

Acknowledgements

The present study was supported by the National Natural Science Foundation of China (grant no. 81460425 and 81760526), the Yunnan Provincial Research Foundation for
References

1. Zhao P, Dai M, Chen W and Li N: Cancer trends in China. Jpn J Clin Oncol 40: 281-285, 2010.
2. Mariette C, Piessens G and Triboulet JP: Therapeutic strategies in oesophageal carcinoma: Role of surgery and other modalities. Lancet Oncol 8: 545-553, 2007.
3. Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917, 2010.
4. Ell C and Lorenz D: Diagnosis and treatment of oesophageal carcinoma: Changes in every respect. Viszeralmedizin 31: 314, 2015.

5. Acunzo M and Croce CM: MicroRNA in Cancer and Cachexia-A Mini-Review. J Int Med 212 (Suppl 1): S74-S77, 2015.
6. Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 116: 291-297, 2004.
7. Iorio MV and Croce CM: MicroRNAs in cancer: Small molecules with a huge impact. J Clin Oncol 27: 5848-5856, 2009.
8. Li S, Qin X, Li Y, Zhang X, Niu R, Zhang H, Cui A, An W and Wang X: MiR-133a suppresses the migration and invasion of esophageal cancer cells by targeting the EMT regulator SOX4. Am J Transl Res 7: 1390-1403, 2015.
9. Mao Y, Li L, Liu J, Wang L and Zhou Y: MiR-495 inhibits esophageal squamous cell carcinoma progression by targeting Akt1. Oncotarget 7: 51272-51282, 2016.
10. Llambi F and Green DR: Apoptosis and oncogenesis: Give and take in the BCL-2 family. Curr Opin Genet Dev 21: 12-20, 2011.
11. Fulda S, Meyer E and Debatin KM: Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression. Oncogene 21: 2283-2294, 2002.
12. Thoms HC, Dunlop MG and Stark LA: p38-mediated inactivation of cyclin D1/cyclin-dependent kinase 4 stimulates nuclear translocation of RelA and apoptosis in colorectal cancer cells. Cancer Res 67: 1660-1669, 2007.
13. Törmänen-Näpiäkkangas U, Soini Y, Kahlos K, Kinnula V and Pääkkö P: Expression of caspases-3, -6 and -8 and their relation to apoptosis in non-small cell lung carcinoma. Int J Cancer 93: 192-198, 2001.
14. Li YH, Wang C, Meng K, Chen LB and Zhou XF: Influence of survivin and caspase-3 on cell apoptosis and prognosis in gastric carcinoma. World J Gastroenterol 10: 1984-1988, 2004.
15. Li SX, Chai L, Cai ZG, Jin LJ, Chen Y, Wu HR and Sun Z: Expression of survivin and caspase 3 in oral squamous cell carcinoma and peritumoral tissue. Asian Pac J Cancer Prev 13: 5027-5031, 2012.
16. Nassar A, Lawson D, Cotsonis G and Cohen C: Survivin and caspase-3 expression in breast cancer: Correlation with prognostic features, proliferation, angiogenesis, and outcome. Appl Immunohistochem Mol Morphol 16: 113-120, 2008.
17. Hsia JY, Chen CY, Chen JT, Hsu CP, Shai SE, Yang SS, Chuang CY, Wang PY and Miaw J: Prognostic significance of caspase-3 expression in primary resected esophageal squamous cell carcinoma. Eur J Surg Oncol 29: 44-48, 2003.
18. Chen J, Yang H, Wen J, Luo K, Liu Q, Huang Y, Zheng Y, Tan Z, Huang Q and Fu J: NHE9 induces chemoradiotherapy resistance in esophageal squamous cell carcinoma by upregulating the Src/ Akt/catenin pathway and Bcl-2 expression. Oncotarget 6: 12405-12420, 2015.
19. Hendrickson AW, Meng XW and Kaufmann SH: Anticancer therapy: Boosting the bang of Bim. J Clin Invest 118: 3582-3584, 2008.
20. Youle RJ and Strasser A: The BCL-2 protein family: Opposing activities that mediate cell death. Nat Rev Mol Cell Biol 9: 47-59, 2008.
21. Staubert RH, Mann W and Knauer SK: Nuclear and cytoplasmic survivin: Molecular mechanism, prognostic, and therapeutic potential. Cancer Res 67: 5999-6002, 2007.
22. Zhang X, Wang C, Shan S, Liu X, Jiang Z and Ren T: TLR4/ROS/miRNA-21 pathway underlies lipopolysaccharide induced primary tumor outgrowth in lung cancer patients. Oncotarget 7: 42172-42182, 2016.